# DESCRIPTION

## FIELD OF THE INVENTION

- relate to antibodies and antigen-binding fragments

## BACKGROUND

- motivate PRLR blockade for cancer treatment

## BRIEF SUMMARY OF THE INVENTION

- provide anti-PRLR antibodies
- describe antibody structure
- specify HCVR and LCVR sequences
- define HCDR and LCDR sequences
- provide HCVR/LCVR pairs
- specify HCDR3/LCDR3 pairs
- describe set of six CDRs
- provide nucleic acid molecules encoding HCVR
- provide nucleic acid molecules encoding LCVR
- provide nucleic acid molecules encoding HCDR1
- provide nucleic acid molecules encoding HCDR2
- provide nucleic acid molecules encoding HCDR3
- provide nucleic acid molecules encoding LCDR1
- provide nucleic acid molecules encoding LCDR2
- provide nucleic acid molecules encoding LCDR3

## DETAILED DESCRIPTION

- set scope and definitions

### Definitions

- define prolactin receptor
- define monomeric human PRLR
- define dimeric human PRLR
- specify human version of proteins
- define cell surface-expressed PRLR
- define anti-PRLR antibody
- define antibody
- describe antibody structure
- define antigen-binding portion
- list antigen-binding fragments
- describe antibody-dependent cytotoxicity
- define human antibody
- define hinge heterogeneity forms of human antibodies
- motivate structural differences in hinge region isotypes
- define isolated antibody
- describe anti-PRLR antibodies with mutations
- introduce germline mutations
- describe antibodies with conservative substitutions
- define epitope
- define substantial identity and similarity
- explain sequence similarity analysis
- introduce pH-dependent binding characteristics
- define acidic and neutral pH
- describe obtaining antibodies with pH-dependent binding

### Anti-PRLR Antibodies Comprising Fc Variants

- introduce Fc domain mutations for enhanced FcRn binding
- list specific mutations and their effects on antibody binding

### Biological Characteristics of the Antibodies

- introduce high-affinity binding to monomeric human PRLR
- describe dissociative half-life of antibodies
- introduce high-affinity binding to dimeric human PRLR
- describe blocking of prolactin-mediated signaling
- describe non-blocking antibodies
- summarize various biological characteristics of antibodies

### Antibody-Drug Conjugates (ADCs)

- introduce ADCs with anti-PRLR antibodies and therapeutic moieties
- list cytotoxic agents and chemotherapeutic drugs
- introduce radionuclide conjugates
- describe linkers and linker technologies
- introduce specific linker-drug compositions
- describe conjugation methods

### Targeting ADCs to Cells Expressing Low Levels of PRLR

- introduce ADCs targeting cells with low PRLR expression
- describe effective killing of cells with low PRLR expression
- define low PRLR expression levels
- describe effective killing in terms of IC50 values
- summarize ADCs and their effects on tumor growth

### Class I Cytokine Receptor Targeting

- introduce class I cytokine receptor targeting
- describe ADCs against class I cytokine receptors
- define class I cytokine receptors
- categorize heterodimeric class I cytokine receptors
- describe ADCs against heterodimeric and homodimeric class I cytokine receptors

### Epitope Mapping and Related Technologies

- introduce epitope mapping
- describe epitope determination techniques
- define epitope binding
- describe epitope competition and cross-competition
- introduce anti-PRLR antibodies with same epitope
- describe epitope binding assays

### Preparation of Human Antibodies

- describe methods for generating fully human antibodies

### Bioequivalents

- define bioequivalents
- describe variant antibodies and DNA sequences
- discuss pharmaceutical equivalents and alternatives
- provide criteria for bioequivalence
- describe in vivo and in vitro bioequivalence measures
- construct bioequivalent variants of anti-PRLR antibodies
- modify glycosylation characteristics of antibodies
- describe species selectivity and cross-reactivity
- provide anti-PRLR antibodies binding human PRLR and other species
- describe multispecific antibodies
- link antibodies to other functional molecules
- construct bispecific antibodies
- describe therapeutic formulation and administration
- provide pharmaceutical compositions and delivery systems
- discuss controlled release systems
- describe bioequivalents
- specify dosage forms
- define therapeutic uses of antibodies
- list diseases treatable by antibodies
- describe combination therapies
- list additional therapeutically active components
- describe administration regimens
- define initial, secondary, and tertiary doses
- specify frequency of administration
- describe loading and maintenance doses
- outline diagnostic uses of antibodies
- describe detection of PRLR in samples
- list detectable labels or reporter molecules
- specify diagnostic assays
- describe samples for PRLR diagnostic assays
- establish baseline levels of PRLR
- compare PRLR levels in healthy and diseased individuals
- describe uses of anti-PRLR antibodies in cancer treatment
- outline methods for identifying patients treatable with anti-PRLR antibodies

## EXAMPLES

- provide examples of making and using methods and compositions of the invention

### Example 1. Generation of Anti-PRLR Antibodies

- generate anti-PRLR antibodies using VELOCIMMUNE mouse and PRLR-specific immunoassay

### Example 2. Heavy and Light Chain Variable Region Amino Acid and Nucleic Acid Sequences

- describe amino acid and nucleic acid sequences of heavy and light chain variable regions of anti-PRLR antibodies

### Control Constructs Used in the Following Examples

- describe control constructs used for comparative purposes

### Example 3. Surface Plasmon Resonance Derived Binding Affinities and Kinetic Constants of Human Monoclonal Anti-PRLR Antibodies

- determine binding affinities and kinetic constants of human monoclonal anti-PRLR antibodies using surface plasmon resonance

### Example 4A. Anti-PRLR Antibodies Bind to Endogenous and Overexpressed PRLR Cell Lines

- determine ability of anti-PRLR antibodies to selectively bind PRLR expressing cell lines
- assess cell surface expression of PRLR on HEK293/hPRLR cells using FACS analysis
- quantify cell surface copy number of PRLR on various cell lines

### Example 4B. Anti-PRLR Antibodies are Internalized by PRLR-Expressing Cells In Vitro

- assess internalization of anti-PRLR antibodies by PRLR-expressing cells

### Example 5. Anti-PRLR Antibodies Inhibit PRL-Mediated Receptor Activation in Cells Expressing Human PRLR

- examine ability of anti-PRLR antibodies to block PRL-mediated receptor activation
- generate antibody inhibition curves using serially diluted anti-human PRLR antibodies
- determine IC50 values and percent blocking for anti-PRLR antibodies

### Example 6. Preparation and Characterization of Anti-PRLR Antibody Drug Conjugates

- conjugate anti-PRLR antibodies to maytansinoid DM1 through an SMCC linker

### Example 7. Anti-PRLR Antibody-Drug Conjugates Effectively Kill Cells with Low-to-Moderate PRLR Expression Levels as Well as Cells with High PRLR Expression Levels

- generate PRLR-overexpressing cells
- assess cell surface expression of PRLR and ErbB2
- determine cell viability using CCK8 and Hoechst 33342 nuclear stain
- calculate IC50 values from four-parameter logistic equation
- summarize IC50 values and percent cell killing in tables
- compare potency of anti-PRLR-DM1 antibodies
- assess impact of PRLR ligand on PRLR ADC-mediated cell kill
- compare potency of anti-PRLR conjugated antibodies to anti-ErbB2 conjugated antibody
- test additional toxins conjugated to anti-PRLR antibodies
- summarize cell killing results in tables
- introduce in vivo efficacy study
- describe tumor implantation and dosing procedures
- monitor tumor volumes and body weights
- calculate tumor growth inhibition
- summarize results in tables
- discuss anti-tumor efficacy of anti-PRLR-DM1 antibodies
- compare anti-tumor efficacy of anti-PRLR-DM1 antibodies to control reagents
- discuss specificity of anti-PRLR ADCs
- summarize anti-tumor activity of anti-PRLR ADCs

